Peptides / Brain and mood

Natural peptide · 9 amino acids · 848.8 Da

Delta sleep-inducing peptide (DSIP)

Approved in RussiaNot banned in sport

DSIP (delta sleep-inducing peptide) is a nine-amino-acid peptide first described from rabbit blood in 1977, registered in Russia as Deltaran. Most studies are in animals, and small studies in people mostly looked at sleep and also measured hormone and stress levels. PepBank shows 113 results on DSIP from 22 studies in people, and 764 from animal and lab studies. The strongest evidence is a randomized trial in people. Data as of 2026-10-30.

Also known as DSIP, WAGGDASGE, Delta sleep-inducing peptide, Delta-sleep peptide, Emideltide, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu and 1 more

9 amino acids, from first to lastWAGGDASGE

Evidence level: Mostly animal studies764 of 877 results come from studies in animals and lab cells. 22 studies in people.

Results in people

113

13% of 877 results

Results in animals

650

74% of 877 results

Results in lab cells

114

13% of 877 results

From computer models

0% of 877 results

Overview

Delta sleep-inducing peptide (DSIP) at a glance

What it is	Natural peptide, 9 amino acids
Approval	Approved in Russia only (registered as Deltaran / Дельтаран)
In sport	Not listed as banned by WADA
Studies	371 studies with results. 246 of them gave DSIP, with 877 results. 113 in people650 in animals114 in lab cells
Best study in people	Randomized controlled trial with 24 people (2009)
Clinical trials	None registered
Community use	Sleep, falling asleep and sleep quality; Stress modulation at low amounts; Support during opioid or alcohol withdrawal (clinical-research use, reported by one wiki)

The science

What is DSIP?

Nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) characterized from rabbit blood in 1977. Mechanism unknown. A product with synthetic DSIP (Deltaran) is registered in Russia; not approved by FDA or EMA.

Amino acids in one chain

Delta sleep-inducing peptide (DSIP) structure and chemistry

The key facts about the molecule. Long codes are in the closed section below.

Sequence, 9 amino acidsFrom the first amino acid to the last

W1AGG−D5ASG−E

Darker means more water-repelling+ and − show charge in the body

Structure

Delta sleep-inducing peptide (DSIP) is a natural peptide of 9 amino acids, with no ring, no changed amino acids.

Formula

C₃₅H₄₈N₁₀O₁₅

Molecular weight

848.8 g/mol

CAS number

62568-57-4

Development

Deltaran (DSIP + glycine): registration holder Scientific Research Center KOMKON LLC (Russia); manufacturer 'Gos.NII OChB FMBA' (Russia), per Vidal. FDA's briefing, citing Popovich et al. 2003, says Deltaran was designed at the Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences. No developer of the bare peptide identified. Highest phase: past the trial stage (see status).

Identifiers

PubChem 68816, ChEMBL CHEMBL2104403, UNII YN28Z5YZ73

Full sequence, SMILES and InChIKey

Three-letter sequence
H-Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu-OH

InChIKey
ZRZROXNBKJAOKB-GFVHOAGBSA-N

SMILES
C[C@@H](C(=O)NCC(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N

See charge, composition and 3D structure on the Scientific page

The evidence

What DSIP studies show

Results grouped by what the studies measured. Each card shows where its results come from.

Mostly animal studies764 of 877 results come from studies in animals and lab cells. 22 studies in people.

Sleep

168 results · 56 in people · 109 animal · 3 lab

In people with long-term insomnia, DSIP gave higher measured sleep efficiency than placebo, but the effect was weak. Neuropsychobiology, 1992

Top results

In people with long-term insomnia, DSIP gave higher measured sleep efficiency than placebo, but the effect was weak. (Neuropsychobiology, 1992)
In rats, DSIP or two analogs given in the evening reduced the night-time rise of a pineal enzyme. (Journal of neurochemistry, 1985)
In rat pineal tissue in the lab, DSIP raised NAT activity, a marker of melatonin production. (Journal of neural transmission. General section, 1992)

Hormones

76 results · 17 in people · 29 animal · 30 lab

In healthy men, DSIP did not change the body's own vasopressin levels compared with saline. Hormone research, 1994

Top results

In healthy men, DSIP did not change the body's own vasopressin levels compared with saline. (Hormone research, 1994)
In healthy men, one DSIP injection lowered a stress-hormone marker (ACTH-like) in blood for at least 3 hours compared with saline. (Psychoneuroendocrinology, 1989)
In rats, DSIP raised the amount of substance P in the hypothalamus. (Neuroscience and behavioral physiology, 1992)

Mood, stress and behavior

40 results · 14 in people · 26 animal

In 7 patients with chronic pain, depressive states also fell significantly compared with before treatment, without a placebo group. European neurology, 1984

Top results

In 7 patients with chronic pain, depressive states also fell significantly compared with before treatment, without a placebo group. (European neurology, 1984)
In people withdrawing from alcohol or opiates, DSIP gave a benefit in 48 of 49 evaluable patients. There was no control group. (Neuropsychobiology, 1983)
In people with opiate withdrawal, symptoms went away or improved markedly in 97% after DSIP, without a comparison group. (European neurology, 1984)

Memory and thinking

9 results · 6 in people · 3 animal

In middle-aged people with chronic insomnia, daytime alertness was higher after DSIP treatment. European neurology, 1987

Top results

In middle-aged people with chronic insomnia, daytime alertness was higher after DSIP treatment. (European neurology, 1987)
In people, DSIP raised alertness while they were awake. (Neuropsychobiology, 1983)
In 7 patients with severe insomnia in an open study, daytime performance improved after DSIP injections. (European neurology, 1984)

Brain and nerves

165 results · 4 in people · 161 animal

In women, DSIP changed how similar the brain waves of the two sides of the brain were. European journal of anaesthesiology, 2009

Top results

In women, DSIP changed how similar the brain waves of the two sides of the brain were. (European journal of anaesthesiology, 2009)
In rats, DSIP changed nearly all measured brain chemicals and blood proteins, and the effects differed by time of day. (Pharmacology, biochemistry, and behavior, 1982)
In rats with induced seizures, DSIP raised the power of slow delta brain waves. (Pharmacology, biochemistry, and behavior, 2004)

Eyes

4 results · 4 in people

In diabetic patients with retinopathy, deltalycyn restored eye responses after bright light faster than in patients with retinopathy who had no treatment. Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi, 2014

Top results

In diabetic patients with retinopathy, deltalycyn restored eye responses after bright light faster than in patients with retinopathy who had no treatment. (Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi, 2014)
In people with diabetic retinopathy, intranasal delta sleep-inducing peptide shortened the delay of the eye's electrical response. (Eksperimental'naia i klinicheskaia farmakologiia, 2014)
In people with diabetic retinopathy, the peptide treatment left the eye's electrical response less weakened after bright light. (Eksperimental'naia i klinicheskaia farmakologiia, 2014)

All 371 DSIP studies by area Open the Scientific page

Key DSIP studies

Studies in people come first, then studies in animals and in the lab.

People
Delta sleep-inducing peptide alters bispectral index, the electroencephalogram and heart rate variability when used as an adjunct to isoflurane anaesthesia
Pomfrett et al. 2009 · European journal of anaesthesiology · 24 people · cited by 8
6 results
People
Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study
Bes et al. 1992 · Neuropsychobiology · 16 people · cited by 8
4 results
People
Reduction of immunoreactive ACTH in plasma following intravenous injection of delta sleep-inducing peptide in man
Bjartell et al. 1989 · Psychoneuroendocrinology · 11 people · cited by 14
4 results
People
Different effects of delta-sleep-inducing peptide on arginine-vasopressin and ACTH secretion in normal men
Chiodera et al. 1994 · Hormone research · 8 people · cited by 8
6 results
People
Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs
Monti et al. 1987 · International journal of clinical pharmacology research · cited by 3
10 results

All 371 Delta sleep-inducing peptide (DSIP) studies

DSIP clinical trials

ClinicalTrials.gov lists no trial of DSIP. A trial under another name may exist.

Status and safety

Is DSIP approved?

FDA

United States

Not approved

No approved medicine contains it.

EMA

European Union

Not approved

No approved medicine contains it.

WADA

Sport

Not banned

Not on the 2026 Prohibited List.

Yes. Approved in Russia only (registered as Deltaran / Дельтаран). No FDA approval and no central EU authorisation (EMA). Not listed as banned by WADA.

Laws and labels change, so check the regulator for the current status.

DSIP side effects and safety

PepBank has 16 safety results from studies of DSIP. 8 of them come from studies in people.

Safety results from studies (16)

In women under anaesthesia, DSIP raised the heart rate. (European journal of anaesthesiology, 2009)
In people given DSIP for withdrawal symptoms, no major side-effect occurred. There was no control group. (Neuropsychobiology, 1983)
In six healthy adults, DSIP did not cause classic sedation on behavioral and brain-wave tests. (International journal of clinical pharmacology, therapy, and toxicology, 1981)
In six middle-aged adults with chronic insomnia, DSIP caused no day-time sedation or other side effects. (Experientia, 1981)
DSIP was well tolerated in people in withdrawal, apart from headaches in a few patients. (European neurology, 1984)
In five studies in people, DSIP injected into a vein was well tolerated. (Neuropsychobiology, 1983)
In women under anaesthesia, DSIP lowered heart rate variability. (European journal of anaesthesiology, 2009)
In six healthy adults, DSIP was well tolerated and no side effects were seen. (International journal of clinical pharmacology, therapy, and toxicology, 1981)
In rabbits, the circulation changes after DSIP stayed within the normal range. (Patologicheskaia fiziologiia i eksperimental'naia terapiia, 1991)
In rats, adding DSIP to valproate did not cause extra movement problems. (Pharmacology, 2006)
In rats, DSIP injected into a movement-control brain area caused slow movement and stiffness. (Biulleten' eksperimental'noi biologii i meditsiny, 1990)
In a small pilot in rats with induced heart attack, all animals given DSIP during the blockage died. (Biomedicines, 2021)
In rabbits, DSIP injected into the brain slightly raised body temperature. (Izvestiia Akademii nauk. Seriia biologicheskaia, 2001)
In rabbits, giving DSIP caused almost no damage to the fine structure of heart muscle. (Biulleten' eksperimental'noi biologii i meditsiny, 1987)
In rats, a lower DSIP dose in the same brain area did not cause slow movement or stiffness. (Biulleten' eksperimental'noi biologii i meditsiny, 1990)
In rats, DSIP injected into another brain area, the caudate nuclei, did not cause slow movement or stiffness. (Biulleten' eksperimental'noi biologii i meditsiny, 1990)

See every safety result on the Scientific page

Doses studied (40 shown)

The doses that these studies used. They are not recommendations.

Dose as reported	Class	Species	Route	Duration	Design	Source
25 nmol/kg body weight	Human	human	intravenous	3 consecutive nights	Randomized trial in people · n = 16	Bes 1992
25 nmol/kg BW	Human	human	intravenous	single dose	Randomized trial in people · n = 11	Bjartell 1989
25 nmol/kg	Human	human	infusion	10-min infusion	Randomized trial in people · n = 8	Chiodera 1994
25 nmol kg(-1)	Human	human	intravenous bolus	Not reported	Randomized trial in people	Pomfrett 2009
25 nmol/kg	Human	human	intravenous	four nights	Randomized trial in people	Monti 1987
25 nmol/kg	Human	human	intravenous	Not reported	Trial in people without random groups · n = 67	Dick 1983
6 X 30 nmol/kg b.w.	Human	human	intravenous	1 week administration, 1 week follow-up	Trial in people without random groups · n = 18	Schneider-Helmert 1986
4 mg	Human	human	intravenous infusion	Not reported	Trial in people without random groups · n = 10	Späth-Schwalbe 1995
25 micrograms/kg bw	Human	human	IV	30 min infusion	Trial in people without random groups · n = 8	Giusti 1993
25 nmol/kg	Human	human	intravenous	Not reported	Trial in people without random groups · n = 6	Schneider-Helmert 1981
25 nmol/kg	Human	human	intravenous	Not reported	Trial in people without random groups · n = 6	Schneider-Helmert 1981
3 and 4 mg total doses	Human	human	intravenous infusion	from 30 min before to 90 min after CRH injection	Trial in people without random groups · n = 5	Späth-Schwalbe 1995
0.0003 g daily	Human	human	intranasal	two months	Trial in people without random groups	Kresiun 2014
25 nmol/kg b.w.	Human	human	injection	single injection	Other study type	Schneider-Helmert 1984
6 nmol/kg	Animal	rabbit	intraventricular infusion	3.5 min	Study in live animals · n = 61	Schoenenberger 1978
60 nM/kg	Animal	rabbit	Not reported	Not reported	Study in live animals · n = 16	Ul'ianinskiĭ 1991
60 nmol/kg	Animal	rabbit	intravenous	Not reported	Study in live animals · n = 11	Pimenova 1991
7 nmol/kg	Animal	cat	intraventricular (lateral ventricle)	single injection, 8 h monitoring	Study in live animals · n = 10	Susić 1987
120 nmol/kg	Animal	cat	subcutaneous	Not reported	Study in live animals · n = 8	Susić 1987
100 micrograms/kg	Animal	rhesus monkey	Not reported	Not reported	Study in live animals · n = 6	Olson 1981
1 or 2 mg	Animal	dog	intravenous	Not reported	Study in live animals · n = 4	Kato 1984
200 microgram	Animal	rat	carotid artery injection	Not reported	Study in live animals	Kastin 1979
7 nmol/kg	Animal	rat	intracerebroventricular	Not reported	Study in live animals	Ursin 1983
100 micrograms/kg bolus	Animal	dog	intravenous	Not reported	Study in live animals	Banks 1982
2.5 nmol	Animal	rat	intracerebroventricular	10 hr	Study in live animals	Inoué 1984
0.1 mg/kg	Animal	rat	peripheral injection	Not reported	Study in live animals	Yehuda 1980
1.0 and 3.0 mg/kg	Animal	rat	peripheral injection	Not reported	Study in live animals	Yehuda 1980
0.1, 1.0 and 3.0 mg/kg	Animal	rat	peripheral injection	Not reported	Study in live animals	Yehuda 1980
2.5 nmol	Animal	rat	intracerebroventricular	10 h	Study in live animals	Inoué 1984
30 nmol/kg	Animal	rat	intravenous	daily evening injections, 3 days	Study in live animals	Graf 1981
5-30 micrograms/kg	Animal	rat	intravenous	Not reported	Study in live animals	Graf 1985
22.5 nmol	Animal	rabbit	intracerebral microinjection	Not reported	Study in live animals	Tissot 1981
15.0 nmol	Animal	rabbit	intracerebral microinjection	Not reported	Study in live animals	Tissot 1981
40-160 nmol/kg	Animal	rat	intraperitoneal	Not reported	Study in live animals	Tobler 1980
7-24 nmol	Animal	rat	intracerebroventricular (lateral or third ventricle)	Not reported	Study in live animals	Tobler 1980
160 nmol/kg	Animal	rat	Not reported	Not reported	Study in live animals	Tobler 1980
80 nmol/kg	Animal	rat	Not reported	Not reported	Study in live animals	Tobler 1980
7 nmol	Animal	rat	intracerebroventricular (third ventricle)	Not reported	Study in live animals	Tobler 1980
25 micrograms/kg i.v.; 1 mg/kg s.c.	Animal	rabbit	intravenous; subcutaneous	Not reported	Study in live animals	Scherschlicht 1984
25 micrograms/kg i.v.; 100 micrograms/kg s.c.	Animal	cat	intravenous; subcutaneous	Not reported	Study in live animals	Scherschlicht 1984

From the community

How people use it

What people report online. It comes from forums and guides, not from studies.

Community-reported. Not tested in trials.

Community sources report that people inject DSIP under the skin in the evening, before bed, to help sleep, in short courses. DSIP has no approved product, and the human research is old and limited.

Reported routines and cautions

What people use it for

Sleep, falling asleep and sleep qualityS1S2
Stress modulation at low amountsS1S2
Support during opioid or alcohol withdrawal (clinical-research use, reported by one wiki)S2

Reported regimens

Regimens that community sources report for DSIP (delta sleep-inducing peptide). Community-reported, not tested in trials.
Context	Route	Amount	How often	How long	Agreement	Sources
Sleep, usual starting amount	subcutaneous injectionTaken in the evening, 30 to 60 minutes before bed.	100 to 200 mcg per dose	once daily, in the evening before bed	2 to 4 weeks (S1); 5 to 10 days (S2)	sources differ: both give 100 to 200 mcg once nightly (S2 also gives a general range of 100 to 300 mcg); the course is 2 to 4 weeks in S1 and 5 to 10 days in S2. Both are wikis and may copy each other, and S1 carries seller links.	S1S2
Sleep, higher amount for severe sleep problems	subcutaneous injection	250 to 500 mcg per dose	once daily before bed	2 to 4 weeks	single source: a wiki that carries seller rankings	S1
Intermittent dosing, reported as a way to limit tolerance	subcutaneous injectionGiven on non-consecutive evenings.	100 to 250 mcg per dose	3 times per week	4 to 6 weeks	single source: a wiki that carries seller rankings	S1

Reported side effects

mild drowsiness or dizziness at the startS2
headacheS2
next-day grogginess at higher amountsS1
rebound insomnia after long use (reported by some community members)S1

Reported benefits (claims, not shown in trials)

better sleep quality and deeper sleepS1S2

Cautions

A community wiki says the long-term safety of repeated DSIP use is unknown. It describes the DSIP research as dated and limited.S1
The community route, subcutaneous injection, was not the route used in the published human DSIP research, which used intravenous infusion. Community amounts are lower than the weight-based trial amounts.S1
Some community members emphasize taking breaks, because of reports of rebound insomnia after long use.S1

Status notes

DSIP is not an approved medicine. On 2026-07-24 the FDA Pharmacy Compounding Advisory Committee voted against recommending emideltide (DSIP) for the 503A bulks list: 7 against, 6 for, 1 abstention. It was the only one of seven peptides not recommended. FDA staff said there was not enough evidence of effectiveness for opioid withdrawal, chronic insomnia and narcolepsy. The vote is a non-binding recommendation. It does not ban DSIP, and it does not approve it.S3 S4

Community sources

S1DSIP: Community Protocols & Reportspeptideprotocolwiki.comcarries seller links, not linked
S2DSIP (Delta Sleep-Inducing Peptide) (opens in a new tab)peptide-db.com
S3FDA panel backs 6 peptides for compounding (opens in a new tab)ajmc.com
S4FDA Advisory Committee Recommends Adding Six of Seven Peptides to Compounding List (opens in a new tab)americanmedspa.org

Gaps

Only two sources give amounts, and both are wiki compilations that may share a base; S1 carries seller rankings. No harm-reduction page, regulator warning or first-hand forum report was found. No checkable source for intranasal use. The regimens R2 and R3 come from S1 only. Two pages from a clinic directory and a telehealth service were removed: they only supported side effects and cautions, and both sell or refer to care. Reddit was not used.

Questions and more

Ask a question about DSIP

The answer links to every study it uses.

What does the evidence say about DSIP?Is DSIP tested in people?Compare with Cerebrolysin Compare with Semax

Sources

Database: PepBank data for DSIP (data version 308560)
Regulator: FDA status record
Regulator: EMA status record
Regulator: WADA status record
Community: community sources (forums and guides), as summarized in the PepBank community file

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Ask your AI about DSIP

Curo is a peptide shop. PepBank and Curo have the same owner. See the Curo catalog (opens in a new tab).

Delta sleep-inducing peptide (DSIP)

Approved in RussiaNot banned in sport

Also known as DSIP, WAGGDASGE, Delta sleep-inducing peptide, Delta-sleep peptide, Emideltide, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu and 1 more

What it is

Natural peptide, 9 amino acids

Approval

Approved in Russia only (registered as Deltaran / Дельтаран)

In sport

Not listed as banned by WADA

Studies

371 studies with results. 246 of them gave DSIP, with 877 results.
113 in people650 in animals114 in lab cells

Best study in people

Randomized controlled trial with 24 people (2009)

Clinical trials

None registered

Community use

Sleep, falling asleep and sleep quality; Stress modulation at low amounts; Support during opioid or alcohol withdrawal (clinical-research use, reported by one wiki)

Dose as reported

Class

Species

Route

Duration

Design

Source

25 nmol/kg body weight

Human

human

intravenous

3 consecutive nights

Randomized trial in people · n = 16

Bes 1992

25 nmol/kg BW

Human

human

intravenous

single dose

Randomized trial in people · n = 11

Bjartell 1989

25 nmol/kg

Human

human

infusion

10-min infusion

Randomized trial in people · n = 8

Chiodera 1994

25 nmol kg(-1)

Human

human

intravenous bolus

Not reported

Randomized trial in people

Pomfrett 2009

25 nmol/kg

Human

human

intravenous

four nights

Randomized trial in people

Monti 1987

25 nmol/kg

Human

human

intravenous

Not reported

Trial in people without random groups · n = 67

Dick 1983

6 X 30 nmol/kg b.w.

Human

human

intravenous

1 week administration, 1 week follow-up

Trial in people without random groups · n = 18

Schneider-Helmert 1986

4 mg

Human

human

intravenous infusion

Not reported

Trial in people without random groups · n = 10

Späth-Schwalbe 1995

25 micrograms/kg bw

Human

human

30 min infusion

Trial in people without random groups · n = 8

Giusti 1993

25 nmol/kg

Human

human

intravenous

Not reported

Trial in people without random groups · n = 6

Schneider-Helmert 1981

25 nmol/kg

Human

human

intravenous

Not reported

Trial in people without random groups · n = 6

Schneider-Helmert 1981

3 and 4 mg total doses

Human

human

intravenous infusion

from 30 min before to 90 min after CRH injection

Trial in people without random groups · n = 5

Späth-Schwalbe 1995

0.0003 g daily

Human

human

intranasal

two months

Trial in people without random groups

Kresiun 2014

25 nmol/kg b.w.

Human

human

injection

single injection

Other study type

Schneider-Helmert 1984

6 nmol/kg

Animal

rabbit

intraventricular infusion

3.5 min

Study in live animals · n = 61

Schoenenberger 1978

60 nM/kg

Animal

rabbit

Not reported

Study in live animals · n = 16

Ul'ianinskiĭ 1991

60 nmol/kg

Animal

rabbit

intravenous

Not reported

Study in live animals · n = 11

Pimenova 1991

7 nmol/kg

Animal

cat

intraventricular (lateral ventricle)

single injection, 8 h monitoring

Study in live animals · n = 10

Susić 1987

120 nmol/kg

Animal

cat

subcutaneous

Not reported

Study in live animals · n = 8

Susić 1987

100 micrograms/kg

Animal

rhesus monkey

Not reported

Study in live animals · n = 6

Olson 1981

1 or 2 mg

Animal

dog

intravenous

Not reported

Study in live animals · n = 4

Kato 1984

200 microgram

Animal

rat

carotid artery injection

Not reported

Study in live animals

Kastin 1979

7 nmol/kg

Animal

rat

intracerebroventricular

Not reported

Study in live animals

Ursin 1983

100 micrograms/kg bolus

Animal

dog

intravenous

Not reported

Study in live animals

Banks 1982

2.5 nmol

Animal

rat

intracerebroventricular

10 hr

Study in live animals

Inoué 1984

0.1 mg/kg

Animal

rat

peripheral injection

Not reported

Study in live animals

Yehuda 1980

1.0 and 3.0 mg/kg

Animal

rat

peripheral injection

Not reported

Study in live animals

Yehuda 1980

0.1, 1.0 and 3.0 mg/kg

Animal

rat

peripheral injection

Not reported

Study in live animals

Yehuda 1980

2.5 nmol

Animal

rat

intracerebroventricular

10 h

Study in live animals

Inoué 1984

30 nmol/kg

Animal

rat

intravenous

daily evening injections, 3 days

Study in live animals

Graf 1981

5-30 micrograms/kg

Animal

rat

intravenous

Not reported

Study in live animals

Graf 1985

22.5 nmol

Animal

rabbit

intracerebral microinjection

Not reported

Study in live animals

Tissot 1981

15.0 nmol

Animal

rabbit

intracerebral microinjection

Not reported

Study in live animals

Tissot 1981

40-160 nmol/kg

Animal

rat

intraperitoneal

Not reported

Study in live animals

Tobler 1980

7-24 nmol

Animal

rat

intracerebroventricular (lateral or third ventricle)

Not reported

Study in live animals

Tobler 1980

160 nmol/kg

Animal

rat

Not reported

Study in live animals

Tobler 1980

80 nmol/kg

Animal

rat

Not reported

Study in live animals

Tobler 1980

7 nmol

Animal

rat

intracerebroventricular (third ventricle)

Not reported

Study in live animals

Tobler 1980

25 micrograms/kg i.v.; 1 mg/kg s.c.

Animal

rabbit

intravenous; subcutaneous

Not reported

Study in live animals

Scherschlicht 1984

25 micrograms/kg i.v.; 100 micrograms/kg s.c.

Animal

cat

intravenous; subcutaneous

Not reported

Study in live animals

Scherschlicht 1984

Context

Route

Amount

How often

How long

Agreement

Sources

Sleep, usual starting amount

subcutaneous injectionTaken in the evening, 30 to 60 minutes before bed.

100 to 200 mcg per dose

once daily, in the evening before bed

2 to 4 weeks (S1); 5 to 10 days (S2)

sources differ: both give 100 to 200 mcg once nightly (S2 also gives a general range of 100 to 300 mcg); the course is 2 to 4 weeks in S1 and 5 to 10 days in S2. Both are wikis and may copy each other, and S1 carries seller links.

S1S2

Sleep, higher amount for severe sleep problems

subcutaneous injection

250 to 500 mcg per dose

once daily before bed

2 to 4 weeks

single source: a wiki that carries seller rankings

Intermittent dosing, reported as a way to limit tolerance

subcutaneous injectionGiven on non-consecutive evenings.

100 to 250 mcg per dose

3 times per week

4 to 6 weeks

single source: a wiki that carries seller rankings

Delta sleep-inducing peptide (DSIP)

Delta sleep-inducing peptide (DSIP) at a glance

What is DSIP?

Delta sleep-inducing peptide (DSIP) structure and chemistry

What DSIP studies show

Sleep

Hormones

Mood, stress and behavior

Memory and thinking

Brain and nerves

Eyes

Key DSIP studies

DSIP clinical trials

Is DSIP approved?

DSIP side effects and safety

How people use it

What people use it for

Reported regimens

Reported side effects

Reported benefits (claims, not shown in trials)

Cautions

Status notes

Community sources

Ask a question about DSIP

Related peptides

Sources

Delta sleep-inducing peptide (DSIP)

Delta sleep-inducing peptide (DSIP) at a glance

What is DSIP?

Delta sleep-inducing peptide (DSIP) structure and chemistry

What DSIP studies show

Sleep

Hormones

Mood, stress and behavior

Memory and thinking

Brain and nerves

Eyes

Key DSIP studies

DSIP clinical trials

Is DSIP approved?

DSIP side effects and safety

How people use it

What people use it for

Reported regimens

Reported side effects

Reported benefits (claims, not shown in trials)

Cautions

Status notes

Community sources

Ask a question about DSIP

Related peptides

Sources